Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2019-04-25 AGM Information
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document explicitly states it contains the "Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)" and details decisions made on April 25, 2019, regarding the approval of financial statements, dividend, board member fees, election of the Board of Directors, remuneration guidelines, and authorization for share issues. These are the typical outcomes and minutes recorded following an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2019-04-25 English
Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is titled "Beslut vid årsstämma i NeuroVive Pharmaceutical AB (publ)" which translates to "Decisions at the Annual General Meeting in NeuroVive Pharmaceutical AB (publ)". The text explicitly summarizes the decisions made during the AGM held on April 25, 2019, covering the approval of 2018 financial statements, dividend decisions, board member elections, remuneration guidelines, and authorization for future share issues. This content directly corresponds to the purpose of an Annual General Meeting (AGM) material.
2019-04-25 Swedish
Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document explicitly announces an 'increase of the number of shares and votes' resulting from a 'preferential rights issue' and a 'directed new issue of shares'. This directly relates to changes in the company's capital structure and share count. Based on the provided definitions, the most appropriate classification is 'Share Issue/Capital Change' (SHA), as it details the final resulting share count after capital-raising activities. It is not a general financing update (CAP) but a specific notification of the resulting share structure change.
2019-03-29 English
Ändring av antal aktier och röster i NeuroVive Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document announces a change in the total number of shares and votes following the completion of a rights issue and a directed new issue. This directly relates to a change in the company's capital structure (share count). The filing explicitly mentions the increase in shares and votes, which aligns with the definition of a Share Issue/Capital Change (SHA). It is not an earnings release, an annual report, or a dividend notice. Given the specific nature of announcing the final share count after a capital event, SHA is the most appropriate classification over the general RNS.
2019-03-29 Swedish
Annual Report 2018
Annual Report Classification · 1% confidence The document is titled 'ÅRSREDOVISNING 2018' (Annual Report 2018) for NeuroVive Pharmaceutical AB. It contains a comprehensive overview of the company's activities, research and development, financial statements (including consolidated and parent company accounts), board of directors' report, and auditor's report. This structure is characteristic of a full Annual Report. FY 2018
2019-03-25 Swedish
Annual Report 2018
Annual Report Classification · 1% confidence The document is explicitly titled 'ANNUAL REPORT 2018' and contains comprehensive sections including a Statutory Administration Report, Financial Statements (Consolidated and Parent Company), Notes, and a CEO statement. It covers the company's full fiscal year performance, strategy, and financial position, which aligns perfectly with the definition of an Annual Report (10-K). FY 2018
2019-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.